Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bettina Engh

Nurse Practitioner Nashville, TN Nurse Practitioner

NPI 1104027184 CMS profile 11241804

3601 Tvc, Nashville, TN 37232

Open in the dashboard

General payments

$17,203

865 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bettina Engh of Nashville, TN is reported in the CMS Open Payments database as having received $17,203 across 865 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,508 137
2024 General $2,768 135
2023 General $3,431 183
2022 General $3,587 192
2021 General $3,909 218

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bettina Engh
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Bettina Engh were reported at $3,508. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Bettina Engh Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,909 $135 $40–$426 $132
2022 $3,587 $152 $48–$470 $149
2023 $3,431 $166 $54–$529 $160
2024 $2,768 $173 $55–$556 $164
2025 $3,508 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,830 152 payments
  2. Abbott Laboratories $2,125 105 payments
  3. Lilly USA, LLC $1,763 97 payments
  4. Amgen Inc. $940 56 payments
  5. Beta Bionics, Inc. $748 24 payments
  6. Xeris Pharmaceuticals, Inc. $704 34 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $648 37 payments
  8. Corcept Therapeutics $631 28 payments
  9. Insulet Corporation $586 31 payments
  10. Sanofi-Aventis U.S. LLC $567 29 payments
  11. Other $5,660 272 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,144 864 payments
  2. Gift $59 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $2,078 121 payments
  2. RYBELSUS $1,743 110 payments
  3. FreeStyle Libre 3 $1,206 58 payments
  4. Tresiba $855 55 payments
  5. FreeStyle Libre 2 $786 41 payments
  6. Korlym $631 28 payments
  7. MOUNJARO $629 29 payments
  8. JARDIANCE $594 32 payments
  9. Omnipod $586 31 payments
  10. Wegovy $511 21 payments
  11. Other $14,391 671 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,706

Median for Nurse Practitioner: 389

Drug cost

$1,171,118

Median for Nurse Practitioner: $21,885

Branded share of claims

75.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 186 $317,931
Jardiance Empagliflozin Brand 118 $122,637
Mounjaro Tirzepatide Brand 74 $82,102
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 52 $81,842
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 39 $67,243
Tresiba Flextouch U-200 Insulin Degludec Brand 46 $66,543
Trulicity Dulaglutide Brand 40 $57,340
Farxiga Dapagliflozin Propanediol Brand 49 $47,228
Tresiba Flextouch U-100 Insulin Degludec Brand 74 $45,387
Humalog Kwikpen U-200 Insulin Lispro Brand 19 $43,886

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$30,708

Medicare's payments for the services billed

Medicare patients

111

Average age 73

Services billed

505

54 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 50%
Chronic kidney disease 45%
Arthritis 42%
Heart failure 21%
Depression 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
$249 — —
JARDIANCE
$199 118 —
GVOKE HYPOPEN
$164 — —
RYBELSUS
$154 — —
Ozempic
$154 186 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

865 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record